PRP4 Induces Epithelial–Mesenchymal Transition and Drug Resistance in Colon Cancer Cells via Activation of p53
Abstract
:1. Introduction
2. Results
2.1. Interaction between PRP4 and p53 Proteins in Various Cancer Cell Lines
2.2. PRP4 Promotes Colorectal Cancer and Activates p53’s Expression In Vivo
2.3. miRNA Profiling and Data Analysis in Parental and PRP4-Transfected Colon Cancer Cells
2.4. PRP4 Mediates Drug Resistance and Antiapoptotic Activity via miR-210’s Upregulation
2.5. PRP4 Activates p53 via Upregulation of miR-210, Inducing EMT and Inhibiting the HCT116 Cell’s Invasion
2.6. The Action of PRP4 Is Mediated through the Activation of HIF-1α and miR-210
2.7. Colon Tumor Induction by PRP4 Is Mediated through the Activation of HIF and miR-210 In Vivo
3. Discussion and Conclusions
4. Materials and Methods
4.1. Chemicals and Reagents
4.2. Cell Culture
4.3. Immunoprecipitation
4.4. In Vitro Kinase Assay
4.5. miRNA and HIF-1α Silencing Using a pLenti-GFP Lentivirus Vector
4.6. Annexin-V-FITC Apoptosis Assay
4.7. F-Actin Staining
4.8. Immunofluorescence Microscopy
4.9. Cell Invasion Assay
4.10. miRNA Microarray
4.11. RT-PCR
4.12. Western Blot
4.13. Animal Study Protocol
4.14. H&E Staining
4.15. Statistical Analysis
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Vousden, K.H.; Prives, C. Blinded by the light: The growing complexity of p53. Cell 2009, 137, 413–431. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Muller, P.A.; Vousden, K.H. p53 mutations in cancer. Nat. Cell Biol. 2013, 15, 2. [Google Scholar] [CrossRef] [PubMed]
- Liu, J.; Zhang, C.; Hu, W.; Feng, Z. Tumor suppressor p53 and its mutants in cancer metabolism. Cancer Lett. 2015, 356, 197–203. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hientz, K.; Mohr, A.; Bhakta-Guha, D.; Efferth, T. The role of p53 in cancer drug resistance and targeted chemotherapy. Oncotarget 2017, 8, 8921–8946. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Huether, A.; Höpfner, M.; Baradari, V.; Schuppan, D.; Scherübl, H. EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem. Pharmacol. 2005, 70, 1568–1578. [Google Scholar] [CrossRef]
- Geisler, S.; Lønning, P.E.; Aas, T.; Johnsen, H.; Fluge, Ø.; Haugen, D.F.; Lillehaug, J.R.; Akslen, L.A.; Børresen-Dale, A.-L. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res. 2001, 61, 2505–2512. [Google Scholar] [PubMed]
- Rusch, V.; Klimstra, D.; Venkatraman, E.; Oliver, J.; Martini, N.; Gralla, R.; Kris, M.; Dmitrovsky, E. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res. 1995, 55, 5038–5042. [Google Scholar] [PubMed]
- Hegi, M.E.; Diserens, A.-C.; Gorlia, T.; Hamou, M.-F.; De Tribolet, N.; Weller, M.; Kros, J.M.; Hainfellner, J.A.; Mason, W.; Mariani, L. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005, 352, 997–1003. [Google Scholar] [CrossRef] [Green Version]
- Dhayat, S.A.; Mardin, W.A.; Seggewiß, J.; Ströse, A.J.; Matuszcak, C.; Hummel, R.; Senninger, N.; Mees, S.T.; Haier, J. MicroRNA profiling implies new markers of gemcitabine chemoresistance in mutant p53 pancreatic ductal adenocarcinoma. PLoS ONE 2015, 10, e0143755. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fuchs-Young, R.; Shirley, S.H.; Lambertz, I.; Colby, J.K.; Tian, J.; Johnston, D.; Gimenez-Conti, I.B.; Donehower, L.A.; Conti, C.J.; Hursting, S.D. P53 genotype as a determinant of ER expression and tamoxifen response in the MMTV-Wnt-1 model of mammary carcinogenesis. Breast Cancer Res. Treat. 2011, 130, 399–408. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chang, C.-J.; Chao, C.-H.; Xia, W.; Yang, J.-Y.; Xiong, Y.; Li, C.-W.; Yu, W.-H.; Rehman, S.K.; Hsu, J.L.; Lee, H.-H.; et al. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat. Cell Biol. 2011, 13, 317–323. [Google Scholar] [CrossRef]
- Dong, P.; Karaayvaz, M.; Jia, N.; Kaneuchi, M.; Hamada, J.; Watari, H.; Sudo, S.; Ju, J.; Sakuragi, N. Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene 2013, 32, 3286–3295. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bartel, D.P. MicroRNAs: Target recognition and regulatory functions. Cell 2009, 136, 215–233. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shruti, K.; Shrey, K.; Vibha, R. Micro RNAs: Tiny sequences with enormous potential. Biochem. Biophys. Res. Commun. 2011, 407, 445–449. [Google Scholar] [CrossRef]
- Garofalo, M.; Croce, C.M. microRNAs: Master regulators as potential therapeutics in cancer. Annu. Rev. Pharmacol. Toxicol. 2011, 51, 25–43. [Google Scholar] [CrossRef] [PubMed]
- Friedman, R.C.; Farh, K.K.-H.; Burge, C.B.; Bartel, D.P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009, 19, 92–105. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Feng, Z.; Zhang, C.; Wu, R.; Hu, W. Tumor suppressor p53 meets microRNAs. J. Mol. Cell Biol. 2011, 3, 44–50. [Google Scholar] [CrossRef]
- Hermeking, H. MicroRNAs in the p53 network: Micromanagement of tumour suppression. Nat. Rev. Cancer 2012, 12, 613. [Google Scholar] [CrossRef] [PubMed]
- Le, M.T.; Teh, C.; Shyh-Chang, N.; Xie, H.; Zhou, B.; Korzh, V.; Lodish, H.F.; Lim, B. MicroRNA-125b is a novel negative regulator of p53. Genes Dev. 2009, 23, 862–876. [Google Scholar] [CrossRef] [Green Version]
- Hu, W.; Chan, C.S.; Wu, R.; Zhang, C.; Sun, Y.; Song, J.S.; Tang, L.H.; Levine, A.J.; Feng, Z. Negative regulation of tumor suppressor p53 by microRNA miR-504. Mol. Cell 2010, 38, 689–699. [Google Scholar] [CrossRef] [Green Version]
- Herrera-Merchan, A.; Cerrato, C.; Luengo, G.; Dominguez, O.; Piris, M.A.; Serrano, M.; Gonzalez, S. miR-33-mediated downregulation of p53 controls hematopoietic stem cell self-renewal. Cell Cycle 2010, 9, 3297–3305. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Swarbrick, A.; Woods, S.L.; Shaw, A.; Balakrishnan, A.; Phua, Y.; Nguyen, A.; Chanthery, Y.; Lim, L.; Ashton, L.J.; Judson, R.L. miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nat. Med. 2010, 16, 1134. [Google Scholar] [CrossRef]
- Kumar, M.; Lu, Z.; Takwi, A.A.L.; Chen, W.; Callander, N.S.; Ramos, K.S.; Young, K.H.; Li, Y. Negative regulation of the tumor suppressor p53 gene by microRNAs. Oncogene 2011, 30, 843. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hoffman, Y.; Pilpel, Y.; Oren, M. microRNAs and Alu elements in the p53–Mdm2–Mdm4 regulatory network. J. Mol. Cell Biol. 2014, 6, 192–197. [Google Scholar] [CrossRef] [Green Version]
- Zhang, C.; Liu, J.; Wang, X.; Wu, R.; Lin, M.; Laddha, S.V.; Yang, Q.; Chan, C.S.; Feng, Z. MicroRNA-339-5p inhibits colorectal tumorigenesis through regulation of the MDM2/p53 signaling. Oncotarget 2014, 5, 9106. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hünten, S.; Siemens, H.; Kaller, M.; Hermeking, H. The p53/microRNA network in cancer: Experimental and bioinformatics approaches. In MicroRNA Cancer Regulation; Springer: Berlin/Heidelberg, Germany, 2013; pp. 77–101. [Google Scholar]
- Rosenberg, G.H.; Alahari, S.K.; Käufer, N.F. prp4 from Schizosaccharomyces pombe, a mutant deficient in pre-mRNA splicing isolated using genes containing artificial introns. Mol. Gen. Genet. MGG 1991, 226, 305–309. [Google Scholar] [CrossRef]
- Kojima, T.; Zama, T.; Wada, K.; Onogi, H.; Hagiwara, M. Cloning of human PRP4 reveals interaction with Clk1. J. Biol. Chem. 2001, 276, 32247–32256. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lützelberger, M.; Käufer, N.F. The Prp4 kinase: Its substrates, function and regulation in pre-mRNA splicing. In Protein Phosphorylation in Human Health; InTech: London, UK, 2012. [Google Scholar]
- Long, J.C.; Caceres, J.F. The SR protein family of splicing factors: Master regulators of gene expression. Biochem. J. 2009, 417, 15–27. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Islam, S.U.; Shehzad, A.; Sonn, J.K.; Lee, Y.S. PRPF overexpression induces drug resistance through actin cytoskeleton rearrangement and epithelial-mesenchymal transition. Oncotarget 2017, 8, 56659. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ahmed, M.B.; Islam, S.U.; Sonn, J.K.; Lee, Y.S. PRP4 kinase domain loss nullifies drug resistance and epithelial-mesenchymal transition in human colorectal carcinoma cells. Mol. Cells 2020, 43, 662. [Google Scholar]
- Minayi, N.; Alizadeh, S.; Dargahi, H.; Soleimani, M.; Khatib, Z.K.; Tayebi, B.; Mohammadian, M.; Alijani, S.; Karami, F. The effect of miR-210 Up-regulation on proliferation and survival of mouse bone marrow derived mesenchymal stem cell. Int. J. Hematol.-Oncol. Stem Cell Res. 2014, 8, 15. [Google Scholar] [PubMed]
- Giannakakis, A.; Sandaltzopoulos, R.; Greshock, J.; Liang, S.; Huang, J.; Hasegawa, K.; Li, C.; O’Brien-Jenkins, A.; Katsaros, D.; Weber, B.L. miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol. Ther. 2008, 7, 255–264. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, Z.; Sun, H.; Dai, H.; Walsh, R.; Imakura, M.; Schelter, J.; Burchard, J.; Dai, X.; Chang, A.N.; Diaz, R.L. MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT. Cell Cycle 2009, 8, 2756–2768. [Google Scholar] [CrossRef] [Green Version]
- Liu, Y.; Bodmer, W.F. Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines. Proc. Natl. Acad. Sci. USA 2006, 103, 976–981. [Google Scholar] [CrossRef] [Green Version]
- Van Bokhoven, A.; Varella-Garcia, M.; Korch, C.; Hessels, D.; Miller, G.J. Widely used prostate carcinoma cell lines share common origins. Prostate 2001, 47, 36–51. [Google Scholar] [CrossRef] [PubMed]
- Fischer, M. Census and evaluation of p53 target genes. Oncogene 2017, 36, 3943–3956. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Islam, S.U.; Ahmed, M.B.; Lee, S.J.; Shehzad, A.; Sonn, J.K.; Kwon, O.-S.; Lee, Y.S. PRP4 kinase induces actin rearrangement and epithelial-mesenchymal transition through modulation of the actin-binding protein cofilin. Exp. Cell Res. 2018, 369, 158–165. [Google Scholar] [CrossRef] [PubMed]
- Bielenberg, D.R.; Zetter, B.R. The Contribution of Angiogenesis to the Process of Metastasis. Cancer J. 2015, 21, 267–273. [Google Scholar] [CrossRef] [Green Version]
- Cicchillitti, L.; Di Stefano, V.; Isaia, E.; Crimaldi, L.; Fasanaro, P.; Ambrosino, V.; Antonini, A.; Capogrossi, M.C.; Gaetano, C.; Piaggio, G. Hypoxia-inducible factor 1-α induces miR-210 in normoxic differentiating myoblasts. J. Biol. Chem. 2012, 287, 44761–44771. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- McCormick, R.; Blick, C.; Ragoussis, J.; Schoedel, J.; Mole, D.; Young, A.; Selby, P.; Banks, R.; Harris, A. miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis. Br. J. Cancer 2013, 108, 1133. [Google Scholar] [CrossRef]
- Noman, M.Z.; Buart, S.; Romero, P.; Ketari, S.; Janji, B.; Mari, B.; Mami-Chouaib, F.; Chouaib, S. Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. Cancer Res. 2012, 72, 4629–4641. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Blandino, G.; Di Agostino, S. New therapeutic strategies to treat human cancers expressing mutant p53 proteins. J. Exp. Clin. Cancer Res. 2018, 37, 30. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cadwell, C.; Zambetti, G.P. The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene 2001, 277, 15–30. [Google Scholar] [CrossRef]
- Donehower, L.A.; Lozano, G. 20 years studying p53 functions in genetically engineered mice. Nat. Rev. Cancer 2009, 9, 831–841. [Google Scholar] [CrossRef]
- Vousden, K.H.; Lane, D.P. p53 in health and disease. Nat. Rev. Mol. Cell Biol. 2007, 8, 275. [Google Scholar] [CrossRef] [PubMed]
- Muller, P.A.; Caswell, P.T.; Doyle, B.; Iwanicki, M.P.; Tan, E.H.; Karim, S.; Lukashchuk, N.; Gillespie, D.A.; Ludwig, R.L.; Gosselin, P. Mutant p53 drives invasion by promoting integrin recycling. Cell 2009, 139, 1327–1341. [Google Scholar] [CrossRef] [PubMed]
- Ohashi, S.; Natsuizaka, M.; Wong, G.S.; Michaylira, C.Z.; Grugan, K.D.; Stairs, D.B.; Kalabis, J.; Vega, M.E.; Kalman, R.A.; Nakagawa, M. Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors. Cancer Res. 2010, 70, 4174–4184. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Roger, L.; Jullien, L.; Gire, V.; Roux, P. Gain of oncogenic function of p53 mutants regulates E-cadherin expression uncoupled from cell invasion in colon cancer cells. J. Cell Sci. 2010, 123, 1295–1305. [Google Scholar] [CrossRef] [Green Version]
- Hua, Z.; Lv, Q.; Ye, W.; Wong, C.-K.A.; Cai, G.; Gu, D.; Ji, Y.; Zhao, C.; Wang, J.; Yang, B.B. MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS ONE 2006, 1, e116. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Camps, C.; Buffa, F.M.; Colella, S.; Moore, J.; Sotiriou, C.; Sheldon, H.; Harris, A.L.; Gleadle, J.M.; Ragoussis, J. hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin. Cancer Res. 2008, 14, 1340–1348. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fasanaro, P.; D’Alessandra, Y.; Di Stefano, V.; Melchionna, R.; Romani, S.; Pompilio, G.; Capogrossi, M.C.; Martelli, F. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J. Biol. Chem. 2008, 283, 15878–15883. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pulkkinen, K.; Malm, T.; Turunen, M.; Koistinaho, J.; Ylä-Herttuala, S. Hypoxia induces microRNA miR-210 in vitro and in vivo. FEBS Lett. 2008, 582, 2397–2401. [Google Scholar] [CrossRef] [Green Version]
- Kulshreshtha, R.; Ferracin, M.; Negrini, M.; Calin, G.A.; Davuluri, R.V.; Ivan, M. Regulation of microRNA expression: The hypoxic component. Cell Cycle 2007, 6, 1425–1430. [Google Scholar] [CrossRef]
- Chan, S.Y.; Loscalzo, J. MicroRNA-210: A unique and pleiotropic hypoxamir. Cell Cycle 2010, 9, 1072–1083. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Islam, S.U.; Ahmed, M.B.; Sonn, J.-K.; Jin, E.-J.; Lee, Y.-S. PRP4 Induces Epithelial–Mesenchymal Transition and Drug Resistance in Colon Cancer Cells via Activation of p53. Int. J. Mol. Sci. 2022, 23, 3092. https://doi.org/10.3390/ijms23063092
Islam SU, Ahmed MB, Sonn J-K, Jin E-J, Lee Y-S. PRP4 Induces Epithelial–Mesenchymal Transition and Drug Resistance in Colon Cancer Cells via Activation of p53. International Journal of Molecular Sciences. 2022; 23(6):3092. https://doi.org/10.3390/ijms23063092
Chicago/Turabian StyleIslam, Salman Ul, Muhammad Bilal Ahmed, Jong-Kyung Sonn, Eun-Jung Jin, and Young-Sup Lee. 2022. "PRP4 Induces Epithelial–Mesenchymal Transition and Drug Resistance in Colon Cancer Cells via Activation of p53" International Journal of Molecular Sciences 23, no. 6: 3092. https://doi.org/10.3390/ijms23063092